Clinical Trials Logo

Leukemia, Myeloid, Acute clinical trials

View clinical trials related to Leukemia, Myeloid, Acute.

Filter by:

NCT ID: NCT00795769 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

Start date: August 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients undergoing stem cell transplant.

NCT ID: NCT00795548 Completed - Clinical trials for Acute Myeloid Leukemia

Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation

Start date: November 2008
Phase: Phase 2
Study type: Interventional

This open label phase-II trial evaluates hematological response of an additional treatment with 5-Azacitidine to common DLI in patients with MDS or AML relapsing after allogeneic stem cell transplantation.

NCT ID: NCT00795002 Completed - Clinical trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Start date: November 2008
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying two different schedules of alvocidib to compare how well they work when given together with cytarabine and mitoxantrone in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as alvocidib, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which schedule of alvocidib is more effective when given together with cytarabine and mitoxantrone in treating patients with acute myeloid leukemia.

NCT ID: NCT00789256 Completed - Clinical trials for Myelodysplastic Syndromes

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Start date: September 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).

NCT ID: NCT00788892 Completed - Clinical trials for Acute Myeloid Leukemia

Trial of CPX-351 in Newly Diagnosed Elderly AML Patients

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The study investigates if CPX-351 will be a) more effective than the standard AML treatment and b) more tolerable than the standard AML treatment regimens. The study compares the investigational product CPX-351 vs the standard treatment for AML in this patients age group.

NCT ID: NCT00783653 Completed - Clinical trials for Acute Myeloid Leukemia

Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years

Start date: August 2008
Phase: Phase 1/Phase 2
Study type: Interventional

In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.

NCT ID: NCT00780598 Completed - Clinical trials for Acute Myeloid Leukemia

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML

OPAL
Start date: October 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of tosedostat in elderly patients suffering from refractory or relapsed AML.

NCT ID: NCT00778375 Completed - Clinical trials for Acute Myeloid Leukemia

Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Start date: October 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if clofarabine given in combination with cytarabine and decitabine can help to control the disease in patients with AML or MDS who are 60 years old or older. The safety of this treatment will also be studied.

NCT ID: NCT00775593 Completed - Leukemia Clinical Trials

Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia

AML1107
Start date: December 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving clofarabine together with temsirolimus may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving clofarabine together with temsirolimus works in treating older patients with relapsed or refractory acute myeloid leukemia.

NCT ID: NCT00774046 Completed - Clinical trials for Acute Myeloid Leukemia

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Start date: December 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.